Commercial Testosterone Preparations: What is the Risk for Male Fertility?Jared L Moss, Lindsey E Crosnoe and Edward D Kim*
University of Tennessee Graduate School of Medicine, USA
- *Corresponding Author:
- Edward Kim
University of Tennessee Graduate School of Medicine
1928 Alcoa Highway, Suite 222 Knoxville, TN 37920, USA
E-mail: [email protected]
Received date: May 15, 2013; Accepted date: June 17, 2013; Published date: June 21, 2013
Citation: Moss JL, Crosnoe LE, Kim ED (2013) Commercial Testosterone Preparations: What is the Risk for Male Fertility? J Steroids Horm Sci 4:113. doi:10.4172/2157-7536.1000113
Copyright: © 2013 Moss JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The populations of symptomatic hypogonadal men and men fathering children at later ages are both increasing. Infertility is a potentially detrimental and preventable side effect of exogenous testosterone therapy. While the use of commercially available testosterone products to treat hypogonadism are increasing, very little is known about their specific effects on fertility.
Methods: A PubMed literature search for the years 1944-2013 was completed focusing on studies examining the effect of testosterone replacement therapy on male fertility. A review of U.S. Food and Drug Administration Prescribing Information was performed on commercial testosterone products in the United States. The manufacturers for the testosterone products were individually contacted for additional information regarding testosterone replacement, spermatogenesis, and male infertility. Lastly, the website www.clinicaltrials.gov was accessed for active clinical trials assessing the effect of testosterone preparations on spermatogenesis and male fertility.